SCHEMBL947574

SCHEMBL947574

CN(C)CCN(C)Cc1c[nH]c2ccccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.73
ALDH1A1 P00352 5/20 0.73
MEN1 O00255 4/20 0.73
KDM4E B2RXH2 3/20 0.73
HSD17B10 Q99714 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP2D6 P10635 1/20 0.73
TSHR P16473 1/20 0.73
CYP2C19 P33261 1/20 0.73
HTR1A P08908 4/20 0.69
HTR2A P28223 3/20 0.69
HTR2C P28335 2/20 0.69
HTR2B P41595 2/20 0.69
LMNA P02545 3/20 0.68
GAA P10253 1/20 0.68
SLC6A4 P31645 1/20 0.65
BCHE P06276 2/20 0.63
ACHE P22303 2/20 0.63
TAAR1 Q96RJ0 1/20 0.63
MAPT P10636 4/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27916469 0.86 LMNA (0.66) KMT2AALDH1A1MEN1KDM4EHSD17B10
Gramine SCHEMBL63578 0.84 ALDH1A1 (1.00) KMT2AALDH1A1MEN1KDM4EHSD17B10
Gramine SCHEMBL29351803 0.84 ALDH1A1 (1.00) KMT2AALDH1A1MEN1KDM4EHSD17B10
SCHEMBL31518326 0.84 LMNA (0.64) KMT2AALDH1A1MEN1KDM4EHSD17B10
SCHEMBL22619123 0.83 ALDH1A1 (0.73) KMT2AALDH1A1MEN1KDM4EHSD17B10
SCHEMBL9882807 0.83 KMT2A (0.87) KMT2AALDH1A1MEN1KDM4EHSD17B10
Gramine SCHEMBL9058128 0.83 ALDH1A1 (0.96) KMT2AALDH1A1MEN1KDM4EHSD17B10
Gramine SCHEMBL7434281 0.81 ALDH1A1 (0.93) KMT2AALDH1A1MEN1KDM4EHSD17B10
N,N-Dimethyltryptamine SCHEMBL335710 0.81 HTR2A (1.00) KMT2AALDH1A1MEN1KDM4EHSD17B10
N,N-Dimethyltryptamine SCHEMBL29350959 0.81 HTR2A (1.00) KMT2AALDH1A1MEN1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875605-B2 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea SUVEN LIFE SCIENCES LIMITED (IN) 2011-01-25 US disclosed
EP-1581492-B1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2008-07-16 EP disclosed
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them HTR3A, HTR3C, HTR2C KMT2A 3036/4885ALDH1A1 3230/4885MEN1 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.